Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
Abstract Background Treatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyond progression in patients receiving an anti-PD-1/PD-L1 based regimen fo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-021-08165-0 |
| _version_ | 1819199891375652864 |
|---|---|
| author | Francesco Spagnolo Andrea Boutros Federica Cecchi Elena Croce Enrica Teresa Tanda Paola Queirolo |
| author_facet | Francesco Spagnolo Andrea Boutros Federica Cecchi Elena Croce Enrica Teresa Tanda Paola Queirolo |
| author_sort | Francesco Spagnolo |
| collection | DOAJ |
| description | Abstract Background Treatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyond progression in patients receiving an anti-PD-1/PD-L1 based regimen for an advanced solid tumor. Methods A systematic literature search was performed to identify prospective clinical trials reporting data on overall response rate by immune-related criteria and/or the number of patients treated beyond conventional criteria-defined PD and/or the number of patients achieving a clinical benefit after an initial PD with regimens including an anti-PD-1/PD-L1 agent which received the FDA approval for the treatment of an advanced solid tumor. Results 254 (4.6%) responses after an initial RECIST-defined progressive disease were observed among 5588 patients, based on 35 trials included in our analysis reporting this information. The overall rate of patients receiving treatment beyond progressive disease was 30.2%, based on data on 5334 patients enrolled in 36 trials, and the rate of patients who achieved an unconventional response among those treated beyond progressive disease was 19.7% (based on 25 trials for a total of 853 patients). Conclusion The results of our systematic review support the clinical relevance of unconventional responses to anti-PD-1/PD-L1-based regimens; however, most publications provided only partial information regarding immune-related clinical activity, or did not provide any information at all, highlighting the need of a more comprehensive report of such data in trials investigating immunotherapy for the treatment of patients with advanced tumors. |
| first_indexed | 2024-12-23T03:23:32Z |
| format | Article |
| id | doaj.art-0969a343b3cb44a082488578006189e8 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-23T03:23:32Z |
| publishDate | 2021-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-0969a343b3cb44a082488578006189e82022-12-21T18:01:54ZengBMCBMC Cancer1471-24072021-04-0121111410.1186/s12885-021-08165-0Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic reviewFrancesco Spagnolo0Andrea Boutros1Federica Cecchi2Elena Croce3Enrica Teresa Tanda4Paola Queirolo5Medical Oncology 2, IRCCS Ospedale Policlinico San MartinoMedical Oncology 2, IRCCS Ospedale Policlinico San MartinoMedical Oncology 2, IRCCS Ospedale Policlinico San MartinoMedical Oncology 2, IRCCS Ospedale Policlinico San MartinoMedical Oncology 2, IRCCS Ospedale Policlinico San MartinoMelanoma, Sarcoma & Rare Tumors Division, European Institute of Oncology (IEO)Abstract Background Treatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyond progression in patients receiving an anti-PD-1/PD-L1 based regimen for an advanced solid tumor. Methods A systematic literature search was performed to identify prospective clinical trials reporting data on overall response rate by immune-related criteria and/or the number of patients treated beyond conventional criteria-defined PD and/or the number of patients achieving a clinical benefit after an initial PD with regimens including an anti-PD-1/PD-L1 agent which received the FDA approval for the treatment of an advanced solid tumor. Results 254 (4.6%) responses after an initial RECIST-defined progressive disease were observed among 5588 patients, based on 35 trials included in our analysis reporting this information. The overall rate of patients receiving treatment beyond progressive disease was 30.2%, based on data on 5334 patients enrolled in 36 trials, and the rate of patients who achieved an unconventional response among those treated beyond progressive disease was 19.7% (based on 25 trials for a total of 853 patients). Conclusion The results of our systematic review support the clinical relevance of unconventional responses to anti-PD-1/PD-L1-based regimens; however, most publications provided only partial information regarding immune-related clinical activity, or did not provide any information at all, highlighting the need of a more comprehensive report of such data in trials investigating immunotherapy for the treatment of patients with advanced tumors.https://doi.org/10.1186/s12885-021-08165-0MelanomaImmunotherapyImmune-related response criteriaTreatment beyond progressionAnti-PD-1 |
| spellingShingle | Francesco Spagnolo Andrea Boutros Federica Cecchi Elena Croce Enrica Teresa Tanda Paola Queirolo Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review BMC Cancer Melanoma Immunotherapy Immune-related response criteria Treatment beyond progression Anti-PD-1 |
| title | Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review |
| title_full | Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review |
| title_fullStr | Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review |
| title_full_unstemmed | Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review |
| title_short | Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review |
| title_sort | treatment beyond progression with anti pd 1 pd l1 based regimens in advanced solid tumors a systematic review |
| topic | Melanoma Immunotherapy Immune-related response criteria Treatment beyond progression Anti-PD-1 |
| url | https://doi.org/10.1186/s12885-021-08165-0 |
| work_keys_str_mv | AT francescospagnolo treatmentbeyondprogressionwithantipd1pdl1basedregimensinadvancedsolidtumorsasystematicreview AT andreaboutros treatmentbeyondprogressionwithantipd1pdl1basedregimensinadvancedsolidtumorsasystematicreview AT federicacecchi treatmentbeyondprogressionwithantipd1pdl1basedregimensinadvancedsolidtumorsasystematicreview AT elenacroce treatmentbeyondprogressionwithantipd1pdl1basedregimensinadvancedsolidtumorsasystematicreview AT enricateresatanda treatmentbeyondprogressionwithantipd1pdl1basedregimensinadvancedsolidtumorsasystematicreview AT paolaqueirolo treatmentbeyondprogressionwithantipd1pdl1basedregimensinadvancedsolidtumorsasystematicreview |